April 16, 2025

E-Cigs + Cigarettes: Worse Disease Odds

"There is a need to reassess the assumption that e-cigarette use provides substantial harm reduction across all cigarette-caused diseases, particularly accounting for dual use," warns a comprehensive meta-analysis.

Conexiant

April 16, 2025

CONSORT 2025: Setting New Standards for Clinical Trial Reporting

"Readers should not have to infer what was probably done; they should be told explicitly." This principle drives the comprehensive CONSORT 2025 update, with its 7 new checklist items aimed at improving clinical trial transparency.

Conexiant

April 14, 2025

FDA-Approved COVID-19 Drugs: Safety Risks Assessed

Researchers found most FDA-authorized COVID-19 treatments were not linked to serious adverse events, though risks may rise with tocilizumab or convalescent plasma in specific patients.

Conexiant

April 11, 2025

New Meta-Analysis Updates Vitamin D Evidence

This meta-analysis of 46 randomized trials found no statistically significant effect of vitamin D supplementation on acute respiratory infection prevention overall or across subgroups.

Conexiant

April 11, 2025

Early Antibiotics Linked to Asthma, Eczema

Researchers found early-life antibiotic use was linked to increased risk of asthma and eczema, but not most other immune diseases, after adjusting for familial factors.

Conexiant

April 10, 2025

Study: LLMs Show Biases in Medical Decision-Making

Large language models recommend different care based on patients' race, housing status, income level, and sexual orientation, potentially amplifying health care disparities if deployed without safeguards, researchers find.

Conexiant

April 07, 2025

Pulse Oximeter Bias in ICU Patients?

Pulse oximetry may be unreliable in diverse patient populations.

Conexiant

April 04, 2025

First IgG4-RD Treatment Approved

A humanized monoclonal antibody that targets CD19+ B cells is first FDA-approved treatment for immunoglobulin G4–related disease, reducing flare risk and glucocorticoid use in clinical trials.

Conexiant

April 03, 2025

Depemokimab Reduces Nasal Polyps, Obstruction in CRSwNP

Depemokimab significantly reduced nasal polyp scores and obstruction symptoms in patients with chronic rhinosinusitis in the ANCHOR-1 and ANCHOR-2 trials. The data support depemokimab as a twice-yearly treatment option, researchers reported.

Conexiant